🧮 BCLI Revenue Breakdown
Understanding Revenue
Revenue, also called sales or the "top line," represents the total income a company generates from its business activities before any costs are deducted. For BCLI, the trailing twelve month revenue is N/A.
Why Revenue Matters
Revenue is the foundation of all financial analysis. A company cannot have sustainable profits without revenue, and revenue growth often drives stock price appreciation. However, revenue alone doesn't tell the full story - it must be analyzed alongside profitability metrics.
BCLI's revenue growth rate of N/A (based on log-linear regression of 0 quarters) indicates relatively flat or slightly declining sales.
Revenue vs Profitability Metrics
Free Cash Flow: $0 →
The cash remaining after capital expenditures. High revenue with negative FCF may indicate heavy reinvestment or poor cash conversion.
Owner Earnings: N/A →
Buffett's metric for true cash generation. Compares revenue's conversion to actual owner value.
Earnings Per Share: $-0.86 →
Net income per share. The bottom line result of all revenue after costs, taxes, and interest.
Net Income: $-10.5M
What remains after all expenses. Net margin shows what percentage of revenue becomes profit.
Price/Sales Ratio Analysis
BCLI's P/S ratio of N/A means investors pay $N/A for every $1 of annual revenue.
Gross Margin: Revenue Quality
Gross margin of N/A shows how much of BCLI's revenue remains after direct costs.
Summary: BCLI Revenue Trend
A reliable trailing-twelve-month revenue figure for BRAINSTORM CELL THERAPEUTICS INC. (BCLI) is not available from its recent SEC filings, so Zyberno does not publish one. This page is excluded from search indexing until the data is available. For complete financial analysis, view the full BCLI stock report on Zyberno.
Frequently Asked Questions
What is BCLI's current revenue?
BRAINSTORM CELL THERAPEUTICS INC.'s trailing twelve month (TTM) revenue is N/A, growing at N/A annually — a negative trend — revenue erosion that warrants monitoring.
Is BCLI's revenue growing?
A reliable trailing-twelve-month revenue figure for BRAINSTORM CELL THERAPEUTICS INC. (BCLI) is not available from its recent SEC filings, so Zyberno does not publish one. This page is excluded from search indexing until the data is available.
What is BCLI's gross margin?
BCLI's gross margin is N/A.
What is BCLI's Price/Sales ratio?
BCLI's P/S ratio is N/A, meaning the market values the company at N/A times its annual revenue.
How does revenue differ from profit?
Revenue is the total income before any expenses, while profit (net income) is what remains after all costs. BCLI's revenue is N/A with a net income of $-10.5M, showing a net profit margin of N/A%.
📊 Full BCLI Stock Report →
See BCLI's intrinsic value, margin of safety, DCF valuation, and complete financial analysis with 250+ metrics.
💵 BCLI Free Cash Flow →
Compare to Free Cash Flow which subtracts all capital expenditures, not just maintenance CapEx.
💰 BCLI Owner Earnings →
Compare to Buffett's Owner Earnings metric which uses maintenance CapEx instead of total capital expenditures.
📈 BCLI Earnings Per Share →
Analyze EPS trends, P/E ratio, earnings yield, and per-share profitability metrics.
🎯 BCLI Earnings Surprise (SUE) →
See whether BCLI is beating or missing its own earnings trend — Standardized Unexpected Earnings and post-earnings drift.
📊 BCLI Revenue →
Analyze revenue trends, growth rate, P/S ratio, and top-line sales performance.
💰 BCLI Net Income →
Analyze the bottom-line profit, P/E ratio, and net profit margin trends.
🔶 BCLI Operating Income →
Analyze EBIT, operating margin, and core business profitability before interest and taxes.
💜 BCLI Gross Profit →
Analyze gross margin, pricing power, and profitability before operating expenses.